Conciseness

The body assumes Claude's competence (no explaining what limma or GEO is) and is dense with substantive rules, but it has recurring redundancy: the Step 5 figure list (Fig 1–8 + tables) and Step 9 upgrade-impact list duplicate the full contents of references/figure_plan_template.md and references/upgrade_path.md; the zero-intersection recovery sequence appears three times (fault-tolerance block, R guideline 2, and twice in the code template); Hard Rules 6–8 restate the Step 6/7 caveats. This is "mostly efficient but includes some unnecessary explanation or could be tightened" (anchor 3) rather than anchor 4's "minor instances", because the duplication is systematic rather than incidental.

Actionability

Every module gets concrete methods, named tools, and specific thresholds ("logFC > 1–2, adj.p < 0.05", "STRING confidence score > 0.4", "CytoHubba ≥5 algorithms", "AUC > 0.70"), and the R template's DEG section is executable as written. Anchor 5 is not reached because the template has undefined variables (labels, expr_scores, deg_d2) and omits code for PPI, immune, and GSEA modules — "mostly executable guidance ... with minor gaps" (anchor 4) is the best fit, clearly above anchor 3's pseudocode level.

Workflow Clarity

Nine explicitly sequenced steps with per-step structure (purpose, input, method, parameters, output, failure points, alternatives) and genuine feedback loops: the ordered DEG-intersection recovery sequence, dataset-level downgrade rules, the zero-intersection stop() guard in code, the n<30 AUC-inflation flag with bootstrap CI requirement, and Step 8's feasibility confirmation. This matches anchor 5 (clear sequence, explicit validation steps, feedback loops for error recovery); no checkpoints are missing, so anchor 4 does not fit.

Progressive Disclosure

Structure is good: four real one-level-deep reference files (verified — no nested references), clearly signaled with "→ Full ...: [references/...md]" pointers and a closing Reference Files table mapping each file to content and usage step. It falls short of anchor 5 because content that already lives in the reference files (the full Fig 1–8 list in Step 5, the upgrade-impact ratings in Step 9) is also inlined in the body, so the split between overview and detail is not clean — "minor organization gaps" (anchor 4).

Specificity

The description lists multiple concrete actions — "Generates complete dual-disease transcriptomic + machine learning research designs", "identify shared DEGs, common hub genes, cross-disease biomarkers, or shared molecular mechanisms ... using public GEO data" — and enumerates the full deliverable set ("four workload configurations (Lite / Standard / Advanced / Publication+) with a recommended primary plan, step-by-step workflow, figure plan, validation strategy, minimal executable version, and publication upgrade path"). This matches the anchor for comprehensive coverage of specific concrete actions, exceeding anchor 4 because no meaningful capability gaps remain for this domain.

Completeness

Both questions are explicitly answered: the "what" ("Generates complete dual-disease transcriptomic + machine learning research designs from a user-provided disease pair") and the "when" ("Use when users want to identify shared DEGs ... between two diseases using public GEO data" plus the explicit trigger-phrase list). This directly matches anchor 5: clear what AND when with concrete trigger phrases. Third-person voice ("Generates", "Always outputs") is used throughout, so no voice penalty applies.

Trigger Term Quality

Seven natural trigger phrases span the full range from domain jargon ("shared DEG + PPI + ROC design", "cross-disease hub gene discovery") to plain user language ("I want to study disease X and Y together", "shared biomarker study for two diseases"), plus the "Use when users want to identify shared DEGs, common hub genes..." clause covering synonyms like shared/common/cross-disease. Coverage is comprehensive across the natural ways users would phrase this need; there is no file-extension equivalent in this domain, so anchor 5's intent is fully met.

Distinctiveness Conflict Risk

The niche is sharply defined — dual-disease (pair-based) GEO transcriptomic study design — and every trigger phrase reinforces the two-disease scope ("between disease A and B", "disease X and Y together"), leaving minimal overlap risk with single-disease transcriptomic or general bioinformatics skills. Anchor 5 (clear niche with distinct triggers, minimal conflict risk) is the best fit; anchor 4's "minor overlap risk" would apply if the pair framing were less consistently enforced.